Embarc

Leadership

Mark Schoenebaum, MD

SPACs
1
$100M
Biopharma
HSAC
  1. Registration
  2. IPO
  3. Definitive Agreement
  4. Completed
Completed
Health Sciences Acquisitions Corporation
Immunovant
IMVT207%